HOME >> BIOLOGY >> NEWS
Receptor May Increase Risk Of Urinary Tract Infections

A newly discovered chemical compound on the surface of some women's kidney cells may explain susceptibility to urinary tract infections, according to current research in the journal Biochemistry. The structure, a specific type of compound known as a glycosphingolipid, is suspected to be on urogenital tract cells in about 30% of all men and women and binds strongly to E. coli bacteria.

The research is outlined in the Nov. 21 web edition of Biochemistry, a peer-reviewed journal of the American Chemical Society, the world's largest scientific society. The article will appear in the journal's Dec. 15 print publication.

Previous studies have shown that women without ABO blood group antigens in their bodily secretions are more likely to have recurrent urinary tract infections. These women are missing the biochemical tools that put the finishing touches on a certain chemical called a glycolipid to determine blood type. "So that glycolipid becomes modified in a different way," says lead author Mark R. Stroud, Ph.D. at Northwest Hospital and the University of Washington in Seattle, "and that modification results in a compound that acts as a high affinity receptor for E. coli The big story here is that the compound itself has been identified." The compound, called sialosyl galactosyl globoside or SGG, had previously only been found in some animal cells and human cells in early stages of embryonic development.

E. coli bacteria are responsible for more than 90% of urinary tract infections, which affect an estimated 7 million women each year at a cost exceeding one billion dollars for diagnosis and treatment. Finding this bacteria-binding compound on kidney cells and the researchers have strong evidence it is on other cells lining the urogenital tract as well may provide a strategy to better treat women prone to infection, who often have to take antibiotics constantly.

Those treatment regimens "basically turn someone who is otherwise normal i
'"/>

Contact: Nancy Blount
n_blount@acs.org
202-872-4440
American Chemical Society
11-Dec-1998


Page: 1 2

Related biology news :

1. Receptor found that guides nerve cells to their final connecting sites
2. Receptor could be target for cancer therapy
3. Receptor-dependent protein activation without a receptor
4. Researchers Engineer A Way To Improve T-Cell Receptors
5. Studies At Cedars-Sinai Confirm Identity Of An Elusive Receptor In Human Cells -- A Breakthrough In Understanding, Fighting Septic Shock
6. Scientists Discover Function For Type III TGF-Beta Receptor
7. Antiviral From Advanced Viral Research Corp. Inhibits CCR5 Cell Receptor For HIV
8. Allelix Clones Receptor For Intestinal Growth Factor GLP-2
9. Scientists Discover Key Cog In Receptor That Governs Ripening
10. UCSF/Gladstone Finding May Explain HIVS Ability To Infect Cells Lacking The Key Target Of HIV: The CD4 Receptor
11. New Findings On Receptor Regulation May Lead To Better Drugs For Diabetes

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Receptor May Increase Risk Urinary Tract Infections

(Date:7/8/2015)... July 8, 2015 Summary Pancreatic cancer ... fourth most fatal, with a mortality rate of 10.9 ... of pancreatic cancer patients has highlighted a significant need ... not being met by the current market. A ... products with varying molecule types and mechanisms of action, ...
(Date:7/7/2015)... 2015  Based on its recent analysis of ... Credence ID, LLC with the 2015 Asia-Pacific ... Year Award. Credence ID has developed a low-cost, ... of offering enrollment and identification solutions to the ... was formed by experts from the mobile biometrics ...
(Date:6/30/2015)... YORK , June 30, 2015 To bolster ... security provider HYPR Corp. announced today the addition of two ... will serve as board advisor and David Raviv ... the team underscore HYPR Corp.,s commitment to providing the most ... Dimitri Sirota co-founded Layer 7 Technologies, a provider ...
Breaking Biology News(10 mins):Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3
(Date:7/29/2015)... Station, TX (PRWEB) , ... July 29, 2015 ... ... POD® designer, manufacturer and supplier, announces the launch of their 2nd generation cell ... to the current miniPOD CT, but it also represents a new POD® design. ...
(Date:7/29/2015)... 29, 2015  AmnioChor Inc., an early stage biotech ... pleased to announce that the Musculoskeletal Transplant Foundation of ... invest in their seed round of development of the ... capabilities. AmnioChor,s technology allows cryopreservation of ... stem cells living within those tissues. Amnion is a ...
(Date:7/29/2015)...  Indivior PLC (LON: INDV) today announced that the ... accepted and received Priority Review by the U.S. Food ... overdose. This naloxone nasal spray comes as a pre-filled ... into the nasal mucosa. 1 The device has ... be better equipped to help an opioid overdose victim. ...
(Date:7/29/2015)... QUEBEC CITY , July 29, 2015 /PRNewswire/ ... (the "Company") today announced it has selected an optimized ... important milestone in the development of a new ... The MAPK pathway represents a prime target for ... significant antitumor activities and survival benefits for B-Raf ...
Breaking Biology Technology:G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 2G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 3The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChor 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 3Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 4Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 5Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3
Cached News: